Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Junshi Biosciences Licenses Anti-IL-17A Antibody Roconkibart to Fosun Wanbang for Greater China – $1.34B Deal Secures Commercialization of Phase III-Ready Psoriasis Therapy

Fineline Cube Jul 2, 2026
Company Deals Digital

Insilico Medicine and Takeda Launch $600M Strategic AI Drug Discovery Collaboration – Pharma.AI Platform to Drive Candidate Identification for High-Potential Therapeutic Targets

Fineline Cube Jul 2, 2026
Company Deals

Nona Biosciences and Lonza Forge Strategic Alliance to Develop Best-in-Class Blood-Brain Barrier Penetration Technology for CNS Therapeutics

Fineline Cube Jul 2, 2026
Company Deals

Ipsen to Acquire Memo Therapeutics for €200M Plus Milestones, Gaining Phase II BK Virus Antibody Potravitug for Transplant Nephropathy

Fineline Cube Jul 2, 2026
Company Deals

Ribo Life Science Achieves First Milestone in siRNA Collaboration with Madrigal for MASH Therapeutics

Fineline Cube Jul 2, 2026
Policy / Regulatory

China’s CDE Unveils 108th Batch of Reference Preparations for Generic Drug Evaluation, Adds 28 New Drugs

Fineline Cube Jun 29, 2026
Company Drug

Ocumension Therapeutics Secures NMPA Approval for OT-502, China’s First Single-Dose Sustained-Release Intraocular Steroid for Postoperative Inflammation

Fineline Cube Jul 3, 2026
Company Drug

Hangzhou Adamerck’s Aom0498 Receives NMPA Approval as China’s First Homegrown Neuromuscular Blockade Reversal Agent – Completing Decade-Long National Innovation Program

Fineline Cube Jul 2, 2026
Company Deals

Johnson & Johnson Completes Acquisition of Intra-Cellular Therapies

Fineline Cube Apr 3, 2025

US-based Johnson & Johnson (NYSE: JNJ) announced the completion of its acquisition of fellow American...

Company Deals Medical Device

Yuewei Medtech Secures RMB100 Million in Series A++ Funding for Cardiac Device Development

Fineline Cube Apr 3, 2025

Beijing Yuewei Medical Technology Co., Ltd, a medical device company specializing in coronary heart disease,...

Company

Boehringer Ingelheim Reports 6.1% Sales Growth in 2024, Bolstered by Key Pharmaceuticals

Fineline Cube Apr 3, 2025

Germany-based Boehringer Ingelheim released its 2024 financial report, recording group net sales of EUR 26.8...

Company Deals

GE Healthcare Partners with Probo Medical to Distribute Ultrasound Devices

Fineline Cube Apr 3, 2025

US medical device and life sciences giant GE Healthcare Technologies Inc. (NASDAQ: GEHC) has entered...

Company Drug

Henlius Biotech’s HLX04-O Shows Positive Results in wAMD Phase III Trial

Fineline Cube Apr 3, 2025

China-based Shanghai Henlius Biotech Inc. (HKG: 2696) has announced positive results from the Phase III...

Company Drug

Mabwell Bioscience’s 7MW3711 ADC Receives Clinical Trial Approval in China

Fineline Cube Apr 3, 2025

China-based Mabwell (Shanghai) Bioscience Co., Ltd (SHA: 688062) announced that it has received clinical trial...

Company Deals

Sinovac Partners with CPMA to Advance Vaccine Preventable Disease Initiatives

Fineline Cube Apr 3, 2025

China-based Sinovac Biotech Ltd (NASDAQ: SVA) has entered into a strategic memorandum of understanding (MoU)...

Company Drug

Novartis’ Vanrafia Gets FDA Accelerated Approval for IgAN

Fineline Cube Apr 3, 2025

Switzerland-based Novartis (NYSE: NVS) announced that it has received accelerated approval from the US Food...

Company Deals

Sanofi and Cathay Capital Launch RMB 2 Billion Pharma Innovation Fund in China

Fineline Cube Apr 3, 2025

The Sanofi Cathy Capital Pharmaceutical Innovation Fund, a joint venture between French pharmaceutical giant Sanofi...

Company Medical Device

Sihuan Pharma’s Polycaprolactone Microsphere Filler Gains NMPA Approval

Fineline Cube Apr 3, 2025

China’s Sihuan Pharmaceutical Holdings Group Ltd (HKG: 0460) announced that it has received Category III...

Company Deals Drug

Shionogi Partners with Link Medical for Cefiderocol Development in Australia and New Zealand

Fineline Cube Apr 3, 2025

Japan-based Shionogi Co., Ltd. has entered into an exclusive licensing agreement with Link Medical Products...

Company Deals

WuXi XDC Partners with MABSOFT to Advance Innovative ADC Development

Fineline Cube Apr 3, 2025

China-based WuXi XDC (HKG: 2268), a joint venture between WuXi Biologics (HKG: 2269) and WuXi...

Company Drug

Guojian Qingke Biomedical Gains NMPA Approval for 3D MSCs in Stroke Trials

Fineline Cube Apr 3, 2025

China-based Guojian Qingke Biomedical Technology (Beijing) Co., Ltd. announced that it has received tacit clinical...

Company Drug

Gan & Lee Pharmaceuticals Secures Pakistan Approval for Insulin Glargine Cartridge

Fineline Cube Apr 3, 2025

Gan & Lee Pharmaceuticals (SHA: 603087) has announced the receipt of marketing approval for its...

Company Drug

Biogen’s BIIB080 Receives FDA Fast Track Designation for Alzheimer’s

Fineline Cube Apr 3, 2025

US-based Biogen Inc. (NASDAQ: BIIB) announced that it has received Fast Track designation (FTD) from...

Policy / Regulatory

NMPA Reduces Influenza Vaccine Batch Release Time to 45 Working Days

Fineline Cube Apr 3, 2025

The National Medical Products Administration (NMPA) has issued a notification reducing the time limit for...

Company Deals

Pfizer and Flagship Pioneering Collaborate on AI-Driven Drug Development

Fineline Cube Apr 3, 2025

US pharmaceutical giant Pfizer Inc. (NYSE: PFE) has entered into a collaboration agreement with Flagship...

Company Deals

Nurix Therapeutics Expands Sanofi Partnership with Undisclosed TPD Program

Fineline Cube Apr 3, 2025

US-based targeted protein degradation (TPD) specialist Nurix Therapeutics, Inc. (NASDAQ: NRIX) announced an expanded partnership...

Company

Jiangxi Rimag Lists CT Chest Lesion Data on Shanghai Data Exchange

Fineline Cube Apr 3, 2025

China-based medical imaging expert Jiangxi Rimag Group Co., Ltd (HKG: 2522) has announced the successful...

Company Drug

Novartis’ Fabhalta Approved in China for C3 Glomerulopathy

Fineline Cube Apr 3, 2025

Novartis’ (NYSE: NVS) Fabhalta (iptacopan) has received approval from China’s National Medical Products Administration (NMPA)...

Posts pagination

1 … 207 208 209 … 690

Recent updates

  • Ocumension Therapeutics Secures NMPA Approval for OT-502, China’s First Single-Dose Sustained-Release Intraocular Steroid for Postoperative Inflammation
  • Hotgen Biotech Launches AI Subsidiary to Transform Small Nucleic Acid Drug Discovery
  • Hangzhou Adamerck’s Aom0498 Receives NMPA Approval as China’s First Homegrown Neuromuscular Blockade Reversal Agent – Completing Decade-Long National Innovation Program
  • Junshi Biosciences Licenses Anti-IL-17A Antibody Roconkibart to Fosun Wanbang for Greater China – $1.34B Deal Secures Commercialization of Phase III-Ready Psoriasis Therapy
  • Jingxin Pharmaceutical Secures NMPA Approval for China’s First Generic Cariprazine in Schizophrenia – Capturing Market Opportunity as Reference Product Remains Unlaunched
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

Ocumension Therapeutics Secures NMPA Approval for OT-502, China’s First Single-Dose Sustained-Release Intraocular Steroid for Postoperative Inflammation

Company

Hotgen Biotech Launches AI Subsidiary to Transform Small Nucleic Acid Drug Discovery

Company Drug

Hangzhou Adamerck’s Aom0498 Receives NMPA Approval as China’s First Homegrown Neuromuscular Blockade Reversal Agent – Completing Decade-Long National Innovation Program

Company Deals

Junshi Biosciences Licenses Anti-IL-17A Antibody Roconkibart to Fosun Wanbang for Greater China – $1.34B Deal Secures Commercialization of Phase III-Ready Psoriasis Therapy

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.